KNE Kane Biotech Inc

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the
development and commercialization of products that prevent and remove microbial
biofilms, is pleased to announce it has appointed Pacific Veterinary Sales of
Abbotsford, B.C. as a distribution partner for the upcoming StrixNB pet oral
care product launch in Western Canada. On January 31, 2013 the company launched
a marketing field test for StrixNB in Manitoba through veterinary clinics. The
response in Manitoba has been exceptional with over 84% of the veterinary
clinics signing up for the Company's promotional campaign and 61% of these
clinics placing orders to regularly carry StrixNB in their clinics. 


"Preparations for the launch into Western Canada are well underway and
appointing distribution is an important step for this market of over 1200
veterinary clinics," stated Gord Froehlich, President and CEO of Kane Biotech.
"Since announcing the market field test in Manitoba our team has been working
diligently to prepare for this commercial introduction and have put key systems
in place to meet the growing demand for StrixNB."


Pacific Veterinary Sales has a direct relationship with veterinarians through an
established and dedicated sales team that focuses on veterinarians in Western
Canada and will warehouse, distribute and sell StrixNB to the veterinary market.


"We are delighted to be working with Kane Biotech to launch their revolutionary
new pet oral care product in Western Canada. Our committed core values of
customer care specializing in sales and service of veterinary products, a great
office team, and 60 dedicated staff are all excited to be part of the StrixNB
launch," stated Ken Kasdorf, Director of Sales and Marketing. "We actively
attend, sponsor and participate in veterinary conferences, trade shows and
industry events and are eager to introduce StrixNB to all clinics from large
clinic groups, dental specialists to smaller independent clinics." 


About Pacific Veterinary Sales

Pacific Veterinary Sales is a privately held company established in 1981 and is
an established and source of quality products in the veterinary distribution
market for Western Canada. They have experienced strong growth over the last
twenty years and have an established sales force that focuses on veterinarians
in the three western provinces. They have Veterinary sales representatives on
the road meeting with veterinarians, technicians and support staff in
clinics/hospitals and built great relationships with these accounts.


About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and
commercialization of products that prevent and remove biofilms. Biofilms develop
when bacteria and other microorganisms form a protective matrix that acts as a
shield against attack. When in a biofilm, bacteria become highly resistant to
antibiotics, biocides, disinfectants, high temperatures and host immune
responses. This resiliency contributes to human health problems such as
recurrent urinary tract infections, medical device associated infections and
tooth decay. 


Kane Biotech uses patent protected technologies based on molecular mechanisms of
biofilm formation/dispersal and methods for finding compounds that inhibit or
disrupt biofilms. The Company has evidence that these technologies have
potential to significantly improve the ability to prevent and/or destroy
biofilms in several medical and industrial applications. 


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Kane's early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Kane's filings with Canadian securities regulatory authorities,
as well as Kane's ability to anticipate and manage the risks associated with the
foregoing. Kane cautions that the foregoing list of important factors that may
affect future results is not exhaustive. When relying on Kane's forward-looking
statements to make decisions with respect to Kane, investors and others should
carefully consider the foregoing factors and other uncertainties and potential
events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Kane cannot
provide assurance that actual results will be consistent with these
forward-looking statements. Kane undertakes no obligation to update or revise
any forward-looking statement.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pure Advertising and Marketing
Kam Thindal
604-488-9875
kam@puread.ca


Kane Biotech Inc,
Gord Froehlich
President & CEO
204-477-7592
204-453-1314 (FAX)
ir@kanebiotech.com
www.kanebiotech.com

Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024